RiverVest Venture Partners’ Post

Webinar Recap: Innovations in Cancer Organoid Modelling for Drug Discovery 🎓   Today, I attended an insightful webinar hosted by Labroots and sponsored by Thermo Fisher Scientific, focusing on the latest developments in cancer organoid (tumoroid) technology and its promising implications for drug screening. Here are some key takeaways: · Tumoroids as Powerful Models for Drug Discovery Workflows · Tumoroids offer a more functionally relevant target in functional compound screening assays. · They represent the diversity of donor genetic backgrounds. · Compatible with automation and multiplexed assay readouts. Key Speakers and Topics: 🔬 Dr. Colin Paul (Cell Biology R&D Staff Scientist, Thermo Fisher Scientific) >> Discussed the crucial role of tumoroids in drug discovery. >>Detailed a comprehensive 5-step tumoroid compound screening workflow using colorectal cancer (CRC) as an example. >>Provided future perspectives on tumoroid drug screening. 🔬 Dr. Thierry Jarde (Laboratory Head, Department of Anatomy and Developmental Biology, Monash University) >>Presented on modeling breast cancer using patient-derived tumor organoids. >>Covered current treatments for advanced breast cancer and personalized medicine approaches. >>Showcased the mini breast tumor model and the establishment of organoids from multiple subtypes. >>Discussed the multi-omics characterization of breast cancer organoids (including WES, histology, single-cell RNA sequencing, proteomics, and drug testing). >>Highlighted that breast cancer organoids are amenable to drug testing and can predict therapy responses. The session concluded with a robust Q/A segment, enriching the discussion with practical insights and expert opinions. This webinar highlighted how next-gen tumoroid models, platforms like OncoPro medium, and Single cell RNA sequencing analysis are shaping the future of cancer research and care, making strides toward precision medicine, improving the efficacy of treatments, and reducing drug candidate attrition rates. Thank you to Labroots, Thermo Fisher Scientific, and all the speakers for this enlightening session! #CancerResearch #DrugDiscovery #Organoids #PrecisionMedicine #BreastCancer #ThermoFisherScientific #Labroots #Webinar #bioinformatics #trnascriptomics #scrnaseq #ngs

If you're attending the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, I’m excited to invite you to join me on Tuesday, October 22, 2024, from 9:30 AM – 10:25 AM MT at Poster Forum #8 in the Solution Center for a Special Poster Collection I selected, focused on "Innovative Drug Delivery Systems and Therapeutic Strategies for Cancer Treatment." This session will feature cutting-edge research in cancer therapy from talented postdocs and Ph.D. students, highlighting the following posters: 1) T1330-06-32: Bombesin-Tagged Nanobubbles as Ultrasound Contrast Agents for Prostate Cancer Diagnosis by Aayushi Laliwala, Ph.D., Case Western Reserve University. 2) T1530-01-02: Development of a pH-Responsive Nanocarrier to Deliver Phenelzine for Prostate Cancer Treatment by Karelys Díaz-Dávila, Pharm.D., Palm Beach Atlantic University. 3) T1530-06-33: PAR-1 Selective Antagonist, SCH-79797 Dihydrochloride, Inhibits the Proliferation and Migration of Metastatic Human Prostate Cancer (PC-3) Cells by Akshay Vora, MS, Massachusetts College of Pharmacy and Health Sciences. 4) W1030-04-20: Combination of Multivalent DR5 Receptor Clustering Agonists and Histone Deacetylase Inhibitors for Treatment of Colon Cancer by Jiahui Li, Pharm.D., University of Utah. 5) T1430-05-27: Evaluate pH-Triggered and Sustainable Drug Release for Dendrimer-Based Formulations of STAT3 Inhibitor by Siva Sankara Chenikkayala, PhD, University of Florida. Looking forward to connecting and discussing these exciting innovations! #AAPS2024 #DrugDelivery #CancerResearch #Therapeutics #Pharma #Drugdevelopment #Nanotechnology

🌟 Exciting Publication Alert! 🌟 I'm thrilled to share that our latest review article, titled "Multifaceted Role of Phytoconstituents-Based Nano Drug Delivery Systems in Combating Triple-Negative Breast Cancer (TNBC): A Paradigm Shift from Chemical to Natural," has been published in the prestigious Naunyn-Schmiedeberg's Archives of Pharmacology, a Springer journal with an impressive impact factor of 3.6! 🎉 This comprehensive review delves into the integration of phytoconstituents and nanotechnology to enhance treatment efficacy for TNBC, a highly aggressive and challenging subtype of breast cancer. Our findings highlight the promising role of natural compounds, particularly polyphenols, isoquinoline alkaloids, and isothiocyanates, in conjunction with advanced nanoformulations to target TNBC pathways more effectively. 🔬 Key Highlights: Phytoconstituents: Exploring the therapeutic potential of natural compounds in inhibiting tumor growth, inducing apoptosis, and preventing metastasis. Nanoformulations: Utilizing nanotechnology to improve drug specificity and cellular uptake, minimizing systemic side effects. Molecular Pathways: Understanding the complex molecular mechanisms of TNBC to develop targeted and personalized treatment approaches. This publication is a collaborative effort with esteemed colleagues, including Dr. Sushma Talegaonkar mam and Dr. Sadia Shah mam. Our dedicated team also includes Anandita Nair, Roshni Singh, Namrata Gautam and Shilpi Saxena. Congratulations to everyone involved for this significant achievement! We believe this research marks a major step forward in the fight against TNBC and opens new avenues for more effective and personalized cancer therapies. 📖 Read the full article here: https://lnkd.in/gS9cKNVv #Research #TNBC #BreastCancer #Phytoconstituents #Nanotechnology #DrugDelivery #Oncology #CancerResearch #TeamWork #Innovation #AmityUniversity

🔬 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 𝐚𝐧𝐝 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 🔬- IndustryARC™ Global cancer biomarkers market is projected to grow from USD 24.5 billion in 2024 to USD 42.0 billion by 2029, demonstrating a robust CAGR of 11.3% during forecast period 2024-2030. 👉 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 @ https://lnkd.in/g9RmB-iu Cancer biomarkers are biological molecules found in #blood, #tissues, or other body fluids that indicate the presence, progression, or characteristics of cancer in the body. These #biomarkers can include #genes, proteins, or other #molecular changes that are associated with cancerous cells and may help in detecting cancer early, predicting #disease outcomes, and guiding treatment decisions. #Cancer biomarkers are used in various applications, such as #diagnostic tests, monitoring treatment response, and identifying individuals at higher risk of developing certain cancers. By providing insights into the molecular and #genetic makeup of a tumor, cancer biomarkers play a crucial role in advancing #personalizedmedicine, enabling more #targeted and effective treatment strategies for cancer patients. The growth of the cancer biomarkers market is driven by the increasing prevalence of cancer worldwide, coupled with a rising focus on early detection and personalized treatment. Advances in #genomics, #proteomics, and #bioinformatics have enabled the identification of more precise and diverse biomarkers, allowing for improved diagnosis, prognosis, and #therapy selection. Additionally, government funding and support for cancer research, as well as collaborations between #pharmaceutical companies and research institutions, are accelerating biomarker discovery and development. The integration of biomarker testing in clinical trials and drug development pipelines, along with the development of non-invasive #liquid #biopsy techniques, is further driving market growth. Rising awareness among patients and #healthcare providers about the benefits of biomarker-based diagnostics also contributes to the expanding adoption of cancer biomarker #testing. 👉 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨 @ https://lnkd.in/gqs6d_64 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Thermo Fisher Scientific Abbott Bio-Rad Laboratories Agilent Technologies Illumina QIAGEN BD PerkinElmer Hologic, Inc. Siemens Healthineers Exact Sciences Myriad Genetics GE HealthCare Merck Group Quest Diagnostics Biocartis

Three years ago, I started to develop an idea to accelerate the in vivo screening of targeting aptamers and oligonucleotides. Taking inspiration from the work of George Church, James Dahlman, and others in the field of DNA-encoded libraries (DEL), I wanted to generate a small library of barcoded aptamer formulations and determine their biodistribution in mice bearing xenograft lung cancer harboring oncogenic EGFR mutations. Together with my postdoc mentor, Burke-Aguero Donald and Brian Thomas, we demonstrated that barcoded aptamer technology enables rapid test of tissue targeting and tumor uptake in vivo. Our findings show no correlation between in vitro (cell culture) and in vivo models, suggesting the need of prioritizing studies in animals to improve translation of aptamers and oligonucleotide therapeutics. Our approach also minimizes the use of animals in agreement with the 3Rs since we tested 20 formulations (but could be hundreds or thousands) at once in just a single cohort of mice. This proof-of-principle study was recently published on the journal Nucleic Acid Therapeutics (see link below). I consider this work as a sort of scientific baby due to all love and passion I put into it (from idea crafting to manuscript preparation). Thanks to all co-authors for your help and support along the way. University of Missouri-Columbia #aptamers #RNAoligonucleotides #oligonucleotides #TumorTargeting #barcoding #NGS #RNAtherapeutics #RNA #EGFR #NSCLC

✨ Exciting Research News! ✨ Almost two years ago, I joined the Ungureanu group, driven by the opportunity to work on some truly groundbreaking experiments. Our project aimed to push the boundaries of single-cell transcriptomics (scRNA-Seq) by scaling up the number of samples analyzed in a single run. This expansion allows for more comprehensive drug testing, opening up new possibilities for patient-specific treatment options. After extensive effort, collaboration, and innovation in method development, I’m thrilled to share that our findings have been published! 🎉 https://lnkd.in/ddiEUmEs Our study introduces a cutting-edge pipeline for pharmacotranscriptomic profiling, using live-cell barcoding to analyze gene-regulatory responses to drugs at single-cell resolution. This breakthrough allows us to capture the nuanced, heterogeneous responses of cancer cells—specifically high-grade serous ovarian cancer (HGSOC)—to a panel of 45 drugs across 13 distinct mechanisms of action. Our study focuses on ovarian cancer, but the techniques we've developed hold promise for applications across various diseases and conditions. Please let us know if you see some applicability of this approach to your own research! A huge congratulations especially to our talented first author Alice Dini, the dedicated team, Emilia Piki, Subodh Sharma, Juuli Raivola, Astrid Murumägi, and our inspiring leader Professor Ungureanu.

🚀 𝐀𝐫𝐠𝐢𝐧𝐚𝐬𝐞 𝟏 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐀 𝐆𝐚𝐦𝐞-𝐂𝐡𝐚𝐧𝐠𝐞𝐫 𝐢𝐧 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 🧬 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gUQ5QzEW The Arginase 1 Antibody Market is witnessing rapid growth as the demand for advanced diagnostic tools and therapeutic research in oncology and immunology rises. Arginase 1 is a critical enzyme involved in the urea cycle and has emerged as a key biomarker in cancer, especially in liver cancer diagnostics and immunotherapy research. 📊 Key Market Drivers: Rising Cancer Prevalence: Increasing cases of liver, prostate, and breast cancers are boosting the need for precise diagnostic antibodies, like Arginase 1, to improve patient outcomes. Advancements in Immunotherapy: The antibody is becoming integral in developing novel immunotherapies, targeting tumor environments, and modulating immune responses. Growing Research Initiatives: Increasing investments in cancer research and biomarker discovery are driving the demand for Arginase 1 antibodies for diagnostic and research applications. 🚀 Market Trends: Innovation in Antibody Production: Companies are focusing on enhancing the specificity and efficacy of Arginase 1 antibodies, leading to better diagnostic accuracy. Expanding Applications: Beyond oncology, Arginase 1 antibodies are being explored for use in inflammation, wound healing, and other immune-related diseases. #Company Sino Biological, Inc. ZodelBiotec Ltd. Innovative Research Geno Technology, Inc. Cloud-Clone Corp Biomatik Corporation Assay Genie Creative Diagnostics Thermo Fisher Scientific Cusabio Technology LLC Abbexa Wuhan Fine Biotech Co., Ltd. ZellBio GmbH MyBioSource Shanghai Korain Biotech Co., Ltd. #Type Monoclonal Antibody Polyclonal Antibody #Application Flow Cytometry ELISA Western Blot Immunoprecipitation Immunofluorescence Other #Biotech #Diagnostics #Oncology #Immunotherapy #HealthcareInnovation #CancerResearch

A Complete Guide of "𝐂𝐚𝐧𝐜𝐞𝐫/𝐓𝐮𝐦𝐨𝐫 𝐏𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠" [PDF Guide] ▶ 𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐟𝐨𝐫 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/d4tgEWpT The rise in #cancer cases, the growing research of novel molecules, and the increasing number of genomic research projects have increased the demand for cancer/tumor profiling in current use. The emergence of #cancerprofiling has removed the restraints of traditional cancer/tumor classification approaches, which rely on the morphology of the cancerous cells and the surrounding tissues. Today, cancer/tumor profiling is accepted as the standard technique for classifying tumors, with the guidelines associated with the European Society for Molecular Oncology (ESMO) and the College of American Pathologists (CAP). The profiling of tumors with advanced technologies such as ISH, NGS, IHC, and PCR has successfully analyzed the genes, amplicons, and gene regions with familiar involvement with tumors. This approach, also known as #targetedtreatment, delivers high sensitivity for detecting tumor subclones or rare mutations, providing increased visibility regarding important mutations acting as drivers of cancer. 𝐆𝐫𝐨𝐰𝐭𝐡 𝐅𝐚𝐜𝐭𝐨𝐫𝐬: 1. Increasing Prevalence of Cancer 2. Rising Pharmaceutical R&D Expenditures 3. Growing Number of Targeted Therapies and the Discovery of New Actionable Biomarkers 4. Increasing Investments in #CancerResearch 5. Declining Costs of NGS-based Profiling 6. Advancements in Multi-omics Tumor Profiling ▶ 𝐑𝐞𝐚𝐝 𝐎𝐮𝐫 𝐋𝐚𝐭𝐞𝐬𝐭 𝐁𝐥𝐨𝐠 @ https://lnkd.in/dkYtJJMJ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Exact Sciences Corporation (U.S.), etc. #cancercare #cancertreatment #cancergenomics #precisiononcology #oncology #targetedtherapy #oncologist #nextgenerationsequencing #genomictesting #pcr #tumor #personalizedmedicine #biomarkers #pharmaceuticals #pharmaindustry #biopharmaceuticals #healthcare #research

✨ Every Tuesday, stay at the forefront of #Oncology advancements! Today’s Pharma Daily Digest delivers essential insights and trends shaping the future of #cancer treatments. 🔺Safety Warning: Carcinogenic Impurities Found in Oncology Drugs highlights the critical need for stringent testing to mitigate cancer risks associated with drug impurities. 🔺Oncology Highlights Collaborative Innovations in Nuclear Medicine Amid Cancer Growth. DeepC and PAIRE unite to integrate AI into nuclear medicine, aiming to improve diagnostic and therapeutic capabilities. 🔺Merck Halts KeyVibe Trials After Futility Analysis Signals Setback in Lung Cancer Research. The discontinuation of Phase 3 trials for vibostolimab and pembrolizumab highlights challenges in advancing effective cancer treatments. 🔺AstraZeneca Collaborates with Tracer Biotechnologies to Enhance Cancer Treatment Monitoring. The agreement will utilize innovative ctDNA detection methods, offering a cost-effective alternative to traditional imaging techniques. 🔺Research at Dana-Farber Reveals CBD May Help Reduce Anxiety in Breast Cancer Patients. While the study did not meet its primary endpoint, findings suggest CBD could lower anxiety levels before diagnostic scans. 🔺FDA Grants Breakthrough Therapy Status to GSK's Jemperli, Showcasing 100% Response Rate in Trials. The designation is based on remarkable early trial results, indicating no evidence of disease in all patients treated. 🔺Merck's KEYTRUDA® (pembrolizumab) HCP® Expands Its Reach: Approved for Early-Stage NSCLC Treatment in China. The National Medical Products Administration grants approval based on promising clinical trial results, marking a milestone in cancer treatment. 🔺NeoPhore Ltd Strengthens Leadership: Michael Shih Appointed CEO Amid Successful Series B Financing. The oversubscribed funding round, backed by Bristol Myers Squibb, positions the company for significant growth in cancer immunotherapy. 🔺Pharmaceutical Industry Commits Over $6 Billion to Molecular Glue Degraders, Paving the Way for Innovative Treatments. The investment reflects a strong belief in the efficacy of molecular glue technology to enhance patient outcomes across various diseases. ----- 💡 Don't forget to sign up for daily updates within the pharma and biotech industry. #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #merck #AstraZeneca #Genmab #Merck #bms

An important frontier is now already emerging in oncology diagnostics today, with new biomarker ID studies making great strides in non-invasive testing. Great post I’m happy to pass along on this, thanks. I’m looking forward to getting the first few Pocket BioLogIQ prototypes next week from #GuyPaillet, co-founder of #GeneralVision, and our first #cancerbiomarker detection App will be loaded on it — the demo app for our device’s introduction will be an app for Breast Cancer Detection running on it that was developed by Bioinformatics Professor #DrLydiaBourzarBenlabiod of Acadia University. Lydia is currently already working on another cancer biomarker detection app to be paired with a handheld microarray now in very early development, that would allow in situ cancer detection during curative surgery procedures, while in theater. #BioDesignAnalytics is calling on developers with biotech programming backgrounds to consider developing other biomarker ID solutions for the Pocket BioLogIQ platform, using its powerful RBF/KNN non von Neumann analytics platform. The combination of a small, but very powerful, sort/seek/execute function provided by NeuroMem ASICs cascaded in parallel, along with a Smart SSD, and Lydia’s Biomarker app on a lockable, and interchangeable, FPGA module. The future is now. #NeuroMem #AI #ML #tML #CancerDiagnostics